Premium
Playing Russian Roulette With Tyrosine Kinase Inhibitors
Author(s) -
Szmulewitz R Z,
Ratain M J
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.245
Subject(s) - clinical pharmacology , formulary , dosing , medicine , pharmacology , food and drug administration , therapeutic window , drug , bioavailability , tyrosine kinase , tyrosine kinase inhibitor , intensive care medicine , cancer , receptor
With the advent of molecularly “targeted therapies,” most notably the tyrosine kinase inhibitors (TKIs), there has been a significant shift in our formulary from intravenous to orally administered medications. The effect of food on bioavailability is a significant consideration for many drugs, especially those with a narrow therapeutic window. This article focuses on the complicated issue of oncology drug dosing with respect to food, highlighting the impact of food labeling on patient safety. Clinical Pharmacology & Therapeutics (2013); 93 3, 242–244. doi: 10.1038/clpt.2012.245